# synPHARM tutorial

http://synpharm.guidetopharmacology.org/

A database of ligand-responsive protein sequences derived from the IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb) and the Protein Data Bank (PDB)

For further help with using synPHARM please email enquiries@guidetopharmacology.org

# synPHARM home page



## Further information and help



### About synPHARM

HOME SEARCH LIGANDS SEQUENCES ABOUT

#### The Guide to PHARMACOLOGY

The Guide to PHARMACOLOGY (GtoPdb) is a searchable database with quantitative information on drug targets and the prescription medicines and experimental drugs that act on them. It was originally created in a collaboration between The British Pharmacological Society (BPS) and the International Union of Basic and Clinical Pharmacology (IUPHAR) and is now developed jointly with funding from the Wellcome Trust. It is intended to become a 'one-stop shop' portal to pharmacological information.

This database is an annexe to the Guide to PHARMACOLOGY. All ligands contained here have a corresponding entry in GtoPdb, and all sequences are ultimately derived from an interaction between a GtoPdb ligand and a GtoPdb target.

#### Find out more about GtoPdb here

#### SynPharm

SynPharm is a database of ligand-responsive protein sequences, derived from interactions from the Guide to PHARMACOLOGY and using data from the Protein Data Bank.

The sequences here are obtained by identifying the protein chain that interacts with a ligand for a given Guide to PHARMACOLOGY interaction, determining the binding residues, and producing a continuous 'bind sequence' that can be used to confer drugability to another protein.

Each bind sequence also contains metrics such as atomic contact ratio and proportional length, and visualisations such as the residue distance matrix, to allow you to better judge whether a sequence is likely to be able to fold independently.

The rationale for such a project was to enable the development of orthogonal molecular switches - switches which only respond to an exogenous molecular trigger, which itself will not interfere with endogenous receptors.

### Data content and statistics



### Search synPHARM



#### Sequences

Target name:	
Search More Sequence Search options	 Click here for more target options (see page 6)

### Search Ligands

### Search by chemical property or ligand class

Ligand name:		
Mass greater than:		Mass less than:
H-bond acceptors greater than:		H-bond acceptors less than:
H-bond donors greater than:		H-bond donors less than:
Polar surface area greater than:		Polar surface area less than:
Lipinski rules broken greater than:		Lipinski rules broken less than:
logP greater than:		logP less than:
Ligand type:	All: Synthetic organic: Metabolite: Natural product: Peptide: Inorganic: Antibody:	Approved ligands only?

aich Sequence	3		Search	ı by bi c	nding sequen or target class	ce property
Target name:						
Sequence:				-	Search by ex (for BLAST	kact* seque
Length greater than:		Length less th	an:		GtoPdb's B	LAST featu
Proportional length greater than:		Proportional I than:	ength less			
Internal contacts greater than:		Internal conta	icts less than:			
External contacts greater than:		External cont	acts less than:			
Contact ratio greater than:		Contact ratio	less than:			
Target type:	All: GPCR: VGIC: LGIC:	Lir	nit to ta	rgets i	nteracting	
	Enzyme: Catalytic Receptor:		with ap	prove	d drugs	
	Other Protein:	_			¥	
species:	AII: Human: Mouse:	Sequences w	th approved li	gands only?		
	Rat:					
Search						

\*Note this will only match sequences stored in synPHARM, i.e. sequences extracted from PDB entries, which may often differ from the native protein sequence (the N and C termini can be truncated and sometimes residues differ or are undefined)

### Sequence list

	НОМЕ	SEARCH	LIGANDS	SEQUENCE	ES ABOUT	
	Drua Resp	onsive Se	auences			
			4.0.000			
						Small
All	Approved dru	gs Short	Long	Human	Non-Human	proportional
						length
						Cont
CIICKING	All di	rug-responsive elen	lients which respond	to a Guide to PHAR	MACOLOGY	Sort
the top			ligana (540).			on co
	ID	Target	Species	Ligand	Length Propor	tional length
1190	M <sub>2</sub> recep	tor Human	[ <sup>3</sup> H]QN	IB 303	64.7%	
1460	A <sub>2A</sub> rece	ptor Human	CGS 21	.680 195	59.7%	
1467	A <sub>2A</sub> rece	ptor Human	NECA	195	59.7%	
1469	A <sub>2A</sub> rece	ptor Human	[ <sup>3</sup> H]CG	S 21680 195	59.7%	
1470	A <sub>2A</sub> rece	ptor Human	[ <sup>3</sup> H]NE	CA 195	59.7%	
1490	A <sub>2A</sub> rece	ptor Human	xanthir congen	ne amine 194	58.7%	
1491	A <sub>2A</sub> rece	ptor Human	ZM-24	1385 250	51.0%	
1494	A <sub>2A</sub> rece	ptor Human	[ <sup>3</sup> H]XA	C 194	58.7%	
1495	A <sub>2A</sub> rece	ptor Human	caffein	e 107	32.2%	
1862	β <sub>2</sub> -adren	oceptor Human	(-)-adre	naline 176	37.3%	
1873	β <sub>2</sub> -adren	oceptor Human	ICI 118	551 332	67.6%	
1879	β <sub>2</sub> -adren	oceptor Human	alpren	olol 336	68.4%	
1888	β <sub>2</sub> -adren	oceptor Human	timolo	335	68.2%	
2181	CaS rece	ptor Human	Ca <sup>2+</sup>	8	1.1%	
2310	CCR5	Human	[ <sup>3</sup> H]ma	raviroc 298	71.7%	
2313	CCR5	Human	maravi	roc 298	71.7%	
2478	CRF <sub>2</sub> rec	eptor Human	urocort	in 1 424	87.8%	

Approved drugs = sequences responding to approved drugs

Short = sequences <100 residues in length

Long = sequences >= 100 residues in length

Small proportional length = sequences <30% of original chain length

### Sequence example

# Human beta adrenergic receptor kinase 1

with balanol GtoP Target: beta adrenergic receptor kinase 1

Links to the synPHARM ligand page, and to the GtoPdb target page for more data on this target



Rotatable, scalable 3D image of the interaction structure



### Sequence example continued





Approved = ligands approved for use as drugs by a regulatory body

Synthetic organic = low molecular weight synthetic or semi-synthetic compounds

Metabolite = non-peptidic, biogenic compounds produced by animal life processes, e.g. hormones

Natural product = non-peptidic, biogenic compounds derived from other living organisms

Peptide = synthetic, semi-synthetic and natural peptides

Inorganic = ions and other inorganic compounds

Antibody = experimental and therapeutic monoclonal antibodies

## Ligand example

### crizotinib

Guide to PHARMACOLOGY ID: 4903 CAS Registry No. - 877399-52-5 ChEMBL Ligand - CHEMBL601719 PubChem CID - 11626560 RCSB PDB Ligand - VGH&sid=2XP2 Wikipedia - Crizotinib

Links to other resources with further data on this ligand. The GtoPdb ligand page contains a more extensive set of out-links.



	Molecular Details			
Calculated molecular properties (for definitions see GtoPdb help)	Molecular mass (Da)	449.11853		
	Hydrogen bond acceptors	5		
	Hydrogen bond donors	2		
	Polar surface area (A <sup>2</sup> )	77.99		
	Lipinski rules broken	0		
	logP	2.834		

Other Details				
Ligand type	Synthetic organic			
Radiolabelled	No			
Approved	Yes			
Approval Source	FDA (2011), EMA (2012)			

Ligand class and drug approval status

